Cytokinetics announced positive Phase 3 ACACIA-HCM trial results for aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy. The drug met both dual primary endpoints, showing statistically significant improvements in patient-reported symptoms (KCCQ-CSS) and exercise capacity (pVO2) versus placebo at Week 36. Based on these findings, the company plans to submit a supplemental New Drug Application to the FDA in the fourth quarter of 2026. Cytokinetics is a specialty cardiovascular biopharmaceutical company developing treatments for diseases of cardiac muscle dysfunction.

On August 13, 2026, Cytokinetics filed a complaint in the U.S. District Court for the District of Delaware against Bristol-Myers Squibb Company and MyoKardia, Inc. The lawsuit seeks a declaratory judgment that Cytokinetics does not infringe U.S. Patent No. 12,616,697 and that the patent's claims are invalid. Cytokinetics also requests preliminary and permanent injunctions preventing defendants from threatening or initiating infringement litigation regarding its MYQORZO (aficamten) product, along with an award of costs and attorneys' fees under 35 U.S.C. § 285. The company demanded a jury trial and stated it intends to vigorously assert its legal rights while noting the inherent uncertainty of litigation outcomes. Cytokinetics operates in the biotechnology industry, focusing on the development of novel cardiac muscle activators for treating heart failure.

Cytokinetics reported second quarter 2026 financial results on August 6, 2026. Net product revenue for MYQORZO (aficamten) was $25 million, bringing total revenues to $28.6 million compared to $66.8 million in the prior year period which included significant license and milestone payments. The company reported a net loss of $198.8 million, or $(1.50) per share. Cytokinetics raised approximately $760.1 million from a public equity offering at $71.00 per share, increasing its cash position to $1.7 billion as of June 30, 2026. The company updated its full-year 2026 GAAP combined R&D and SG&A expense guidance upward to $860 million–$890 million. Additionally, Cytokinetics announced positive topline results from the ACACIA-HCM Phase 3 trial for non-obstructive HCM and plans to submit a supplemental New Drug Application in Q4 2026. The company operates as a specialty cardiovascular biopharmaceutical firm developing treatments for cardiac muscle dysfunction.